Javier Pinilla, MD, PhD

Articles

Future Direction in CML: Acknowledging Use of Allogeneic Transplant, Key Challenges, and Unmet Needs

September 24th 2025

Panelists discuss the declining role of allogeneic transplant in chronic myeloid leukemia (CML) due to advances in tyrosine kinase inhibitors (TKIs) while emphasizing ongoing challenges related to treatment tolerability, management of advanced disease, and financial toxicity that necessitate continued research and supportive care strategies.

Clinical Approach to Choice of Third-Line TKI in R/R CML

September 24th 2025

Panelists discuss the critical role of mutation testing and individualized ponatinib dosing in managing resistant or relapsed chronic myeloid leukemia (CML), emphasizing frequent molecular monitoring and multidisciplinary care to balance treatment efficacy with toxicity.

Clinical Perspectives: A 45-Year-Old Man With R/R CML

September 24th 2025

Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.

Treatment-Free Remission in CML: Long-Term Monitoring and Care Approach

September 17th 2025

Panelists discuss the importance of monitoring molecular milestones in chronic myeloid leukemia (CML) to guide treatment response and eligibility for treatment-free remission (TFR), emphasizing the multidisciplinary team’s role—including pharmacists and nurses—in supporting adherence, managing adverse effects, and providing individualized patient care.

First-Line TKI Treatment Selection in Newly Diagnosed CML

September 17th 2025

Panelists discuss the evolving landscape of frontline chronic myeloid leukemia (CML) treatment, highlighting asciminib’s emerging role as a preferred first-line therapy due to its favorable efficacy, tolerability, and potential to simplify treatment selection while supporting long-term goals like deep molecular response and treatment-free remission.

Beyond the Prescriber: Integrating the Multidisciplinary Team Into CML Management

September 10th 2025

Panelists discuss the critical role of early molecular testing and multidisciplinary collaboration—including pharmacists, nurse practitioners, and physicians—in personalizing chronic myeloid leukemia (CML) treatment, managing adverse effects, and supporting patient adherence to optimize long-term outcomes.

The CML Patient Journey: A Multidisciplinary Approach to CML Management

September 10th 2025

Panelists discuss a multidisciplinary approach to managing chronic myeloid leukemia (CML), using a clinical case to highlight the importance of early diagnosis, timely referral to specialized centers, and coordinated care among oncologists, nurse practitioners, and pharmacists to optimize patient outcomes.

Highlighting Key CML/ALL Data Presented at ASH 2024

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Selecting a TKI in Subsequent Lines of Therapy in CML

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Dosing Strategies for Ponatinib in CML and ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Emerging Mutation Analysis from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Factors That Influence Treatment Decisions in Later-Line CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Future Perspectives on the Treatment Landscape for CLL

February 16th 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert Insights into Investigation Therapies for CLL

February 16th 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

February 9th 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 9th 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.